U.S. District Judge Sue Robinson of Delaware surprised financial markets and the pharmaceutical industry Thursday by ordering an FDA-approved cholesterol drug off the market.
Shares of Amgen Inc. jumped 4 percent Friday morning after Robinson granted its request for a permanent injunction that blocks Sanofi and Regeneron Pharmaceuticals Inc. from marketing Praluent, a biological drug that treats high LDL cholesterol. Amgen, which markets the competing biologic Rapatha, prevailed in a patent infringement trial against Sanofi last year.
